Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
Sponsor: Ausper Biopharma Co., Ltd.
Summary
This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).
Official title: A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 1/2 Study to Evaluate AHB-137 Injection Followed by TVAX-008 Injection in Participants With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Analogs
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
105
Start Date
2026-10-31
Completion Date
2029-06-20
Last Updated
2026-10-19
Healthy Volunteers
No
Conditions
Interventions
AHB-137
AHB-137 will be administered per 1 week.
Placebo
Placebo will be used per 4 weeks.
TVAX-008
TVAV-008 will be administered per 4 weeks.